Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ALAS1 is the first and rate-limiting enzyme of the heme biosynthetic pathway in non-erythroid tissues, catalyzing pyridoxal 5'-phosphate (PLP)-dependent condensation of glycine and succinyl-CoA to produce δ-aminolevulinic acid[1][2][6]. It is encoded on human chromosome 3 and ubiquitously expressed; its function is essential for heme production, a vital cofactor in oxygen transport, metabolism, and detoxification enzymes. Deficiency in ALAS1 leads to impaired heme synthesis and can be fatal in developmental stages, while dysregulation can contribute to porphyria, though direct disease linkage in humans is less well-characterized compared to ALAS2[1][2][5][6].
Porphyria therapies (such as hemin) act by feedback inhibition of heme biosynthesis; experimental approaches may target gene/protein expression/PLP cofactor binding
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5-aminolevulinate synthase 1 (mitochondrial) (ALAS1).